A valuable paper examining the presence of AAV manufacturing contaminants in a human patient’s liver. These results will hopefully be leveraged for improving the safety of gene therapies in the future.

Analyses of liver biopsies from a child with spinal muscular atrophy treated with adeno-associated virus gene therapy who developed hepatitis reveal contaminating manufacturing plasmids and disrupted vector genomes, possibly resulting from recombination events.